AZT logo

ArcticZymes Technologies Stock Price

Symbol: OB:AZTMarket Cap: NOK 1.5bCategory: Pharmaceuticals & Biotech

AZT Share Price Performance

NOK 28.60
8.35 (41.23%)
1.4% undervalued intrinsic discount
NOK 29.00
Fair Value
NOK 28.60
8.35 (41.23%)
1.4% undervalued intrinsic discount
NOK 29.00
Fair Value
Price NOK 28.60
AnalystConsensusTarget NOK 29.00

AZT Community Narratives

AnalystConsensusTarget·Updated
Fair Value NOK 29.00 1.4% undervalued intrinsic discount

Biomanufacturing And Gene Therapies Will Expand Precision Medicine

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent AZT News & Updates

What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You

Aug 15
What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You

ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up

Mar 11
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up

ArcticZymes Technologies ASA Key Details

NOK 104.3m

Revenue

NOK 5.0m

Cost of Revenue

NOK 99.3m

Gross Profit

NOK 96.5m

Other Expenses

NOK 2.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
0.055
Gross Margin
95.17%
Net Profit Margin
2.69%
Debt/Equity Ratio
0%

ArcticZymes Technologies ASA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

2 Risks
2 Rewards

About AZT

Founded
1990
Employees
53
CEO
Michael Akoh
WebsiteView website
www.arcticzymes.com

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Market Insight

Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading

Norwegian Market Performance

  • 7 Days: 1.6%
  • 3 Months: 5.7%
  • 1 Year: 7.6%
  • Year to Date: 7.4%
The market is up 1.6% over the last week, with the Energy sector leading the way, up 3.7%. As for the past 12 months, the market is up 7.6%. Earnings are forecast to grow by 12% annually. Market details ›